RT Journal Article
T1 Association between plasma phospholipid saturated fatty acids and metabolic markers of lipid, hepatic, inflammation and glycaemic pathways in eight European countries: a cross-sectional analysis in the EPIC-InterAct study.
A1 Zheng, Ju-Sheng
A1 Sharp, Stephen J
A1 Imamura, Fumiaki
A1 Koulman, Albert
A1 Schulze, Matthias B
A1 Ye, Zheng
A1 Griffin, Jules
A1 Guevara, Marcela
A1 Huerta, José María
A1 Kröger, Janine
A1 Sluijs, Ivonne
A1 Agudo, Antonio
A1 Barricarte, Aurelio
A1 Boeing, Heiner
A1 Colorado-Yohar, Sandra
A1 Dow, Courtney
A1 Dorronsoro, Miren
A1 Dinesen, Pia T
A1 Fagherazzi, Guy
A1 Franks, Paul W
A1 Feskens, Edith J M
A1 Kühn, Tilman
A1 Katzke, Verena Andrea
A1 Key, Timothy J
A1 Khaw, Kay-Tee
A1 de Magistris, Maria Santucci
A1 Mancini, Francesca Romana
A1 Molina-Portillo, Elena
A1 Nilsson, Peter M
A1 Olsen, Anja
A1 Overvad, Kim
A1 Palli, Domenico
A1 Quirós, Jose Ramón
A1 Rolandsson, Olov
A1 Ricceri, Fulvio
A1 Spijkerman, Annemieke M W
A1 Slimani, Nadia
A1 Tagliabue, Giovanna
A1 Tjonneland, Anne
A1 Tumino, Rosario
A1 van der Schouw, Yvonne T
A1 Langenberg, Claudia
A1 Riboli, Elio
A1 Forouhi, Nita G
A1 Wareham, Nicholas J
K1 Even-chain
K1 Glycaemic
K1 Hepatic
K1 Inflammation
K1 Lipids
K1 Metabolic markers
K1 Odd-chain
K1 Saturated fatty acids
K1 Very-long-chain
AB Accumulating evidence suggests that individual circulating saturated fatty acids (SFAs) are heterogeneous in their associations with cardio-metabolic diseases, but evidence about associations of SFAs with metabolic markers of different pathogenic pathways is limited. We aimed to examine the associations between plasma phospholipid SFAs and the metabolic markers of lipid, hepatic, glycaemic and inflammation pathways. We measured nine individual plasma phospholipid SFAs and derived three SFA groups (odd-chain: C15:0 + C17:0, even-chain: C14:0 + C16:0 + C18:0, and very-long-chain: C20:0 + C22:0 + C23:0 + C24:0) in individuals from the subcohort of the European Prospective Investigation into Cancer and Nutrition (EPIC)-InterAct case-cohort study across eight European countries. Using linear regression in 15,919 subcohort members, adjusted for potential confounders and corrected for multiple testing, we examined cross-sectional associations of SFAs with 13 metabolic markers. Multiplicative interactions of the three SFA groups with pre-specified factors, including body mass index (BMI) and alcohol consumption, were tested. Higher levels of odd-chain SFA group were associated with lower levels of major lipids (total cholesterol (TC), triglycerides, apolipoprotein A-1 (ApoA1), apolipoprotein B (ApoB)) and hepatic markers (alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamyl transferase (GGT)). Higher even-chain SFA group levels were associated with higher levels of low-density lipoprotein cholesterol (LDL-C), TC/high-density lipoprotein cholesterol (HDL-C) ratio, triglycerides, ApoB, ApoB/A1 ratio, ALT, AST, GGT and CRP, and lower levels of HDL-C and ApoA1. Very-long-chain SFA group levels showed inverse associations with triglycerides, ApoA1 and GGT, and positive associations with TC, LDL-C, TC/HDL-C, ApoB and ApoB/A1. Associations were generally stronger at higher levels of BMI or alcohol consumption. Subtypes of SFAs are associated in a differential way with metabolic markers of lipid metabolism, liver function and chronic inflammation, suggesting that odd-chain SFAs are associated with lower metabolic risk and even-chain SFAs with adverse metabolic risk, whereas mixed findings were obtained for very-long-chain SFAs. The clinical and biochemical implications of these findings may vary by adiposity and alcohol intake.
YR 2017
FD 2017-11-17
LK http://hdl.handle.net/10668/11807
UL http://hdl.handle.net/10668/11807
LA en
DS RISalud
RD Apr 19, 2025